Breda, the Netherlands/Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology
company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and
cancer, today announced the achievement of its third preclinical milestone from its collaboration with LEO Pharma, following the
approval of the clinical trial application (CTA) filing for ARGX-112.
"This milestone showcases the productivity of our collaboration with LEO Pharma, marking the final step before
ARGX-112 may enter clinical development. It triggers the third of three success-based preclinical milestone payments under this
collaboration. We are convinced of the potential of ARGX-112 to address unmet needs in inflammatory skin diseases and are excited
to see the program approved for clinical development," commented Tim Van Hauwermeiren, CEO at argenx.
In May 2015, argenx entered into a research collaboration and exclusive license option agreement with LEO Pharma
to develop and commercialize ARGX-112, a novel antibody discovered by argenx using its SIMPLE Antibody(TM) technology. During the
collaboration term, argenx successfully concluded all ARGX-112 research and development activities required for the first filing by
LEO Pharma of a CTA.
As part of the agreement, argenx has granted LEO Pharma an exclusive option to obtain a worldwide, exclusive license to the
ARGX-112 program, to develop and commercialize licensed products for inflammatory skin disorders. In addition to the upfront and
preclinical milestone payments, argenx may receive further regulatory and clinical milestone payments up to approximately €100mm as
well as royalties on net sales of any product.
About argenx
argenx a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the
treatment of severe auto-immune diseases and cancer. We are focused on developing product candidates with the potential to be
either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a
significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our
SIMPLE AntibodyTM Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets,
and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product
candidates.
www.argenx.com
About LEO Pharma A/S
LEO Pharma helps people achieve healthy skin. By offering care solutions to patients in more than 100 countries globally, LEO
Pharma supports people in managing their skin conditions. Founded in 1908 and owned by the LEO Foundation, the healthcare company
has devoted decades of research and development to delivering products and solutions to people with skin conditions. LEO Pharma is
headquartered in Denmark and employs around 5,200 people worldwide.
www.leo-pharma.com
For further information, please contact:
Joke Comijn, Corporate Communications and IR Manager
+32 (0)477 77 29 44
+32 (0)9 310 34 19
info@argenx.com
Beth DelGiacco (US IR)
Stern Investor Relations
+1 212 362 1200
beth@sternir.com
Forward-looking Statements
The contents of this announcement include statements that are, or may be deemed to be, "forward-looking
statements." These forward-looking statements can be identified by the use of forward-looking terminology, including the terms
"believes," "estimates," "anticipates," "expects," "intends," "may," "will," or "should," and include statements argenx makes
concerning the encouraging preclinical data of ARGX-112; the potential implications of these data for the future development of
ARGX-112; argenx's advancement of, and anticipated clinical development and regulatory and clinical milestones, royalties, and
plans related to, ARGX-112; and the potential license to LEO Pharma, and potential commercialization, of ARGX-112. By their nature,
forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are
not guarantees of future performance. argenx's actual results may differ materially from those predicted by the forward-looking
statements as a result of various important factors, including argenx's expectations regarding its the inherent uncertainties
associated with competitive developments, preclinical and clinical trial and product development activities and regulatory approval
requirements; argenx's reliance on collaborations with third parties; estimating the commercial potential of argenx's product
candidates; argenx's ability to obtain and maintain protection of intellectual property for its technologies and drugs; argenx's
limited operating history; and argenx's ability to obtain additional funding for operations and to complete the development and
commercialization of its product candidates. A further list and description of these risks, uncertainties and other risks can be
found in argenx's U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx's most recent annual
report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these
uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking
statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise
the information in this press release, including any forward-looking statements, except as may be required by
law.